Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Nasdaq

Why Is Dave Chappelle's Stand-Up Not Included In Netflix's Upcoming Comedy Specials?

Netflix Inc (NASDAQ: NFLX) will not include Dave Chappelle’s segment in the streaming version of its recent comedy festival, but the exclusion is not based on the assault that occurred while Chappelle was in performance.

Benzinga

77 Stocks Moving In Tuesday's Mid-Day Session

Gainers

Benzinga

Ecstasy Research Trial Completes Enrollment, Moves Closer To Approval To Treat PTSD

The non-profit Multidisciplinary Association for Psychedelics Studies (MAPS) and its subsidiary MAPS Public Benefit Corporation finished the enrollment stage for the second Phase 3 clinical trial on MDMA (MAPP2).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

BofA Upgrades O'Reilly After A Relook At Q1 Print

O'Reilly Automotive Inc (NASDAQ: ORLY) is a defensive auto-parts retailer whose stock has moved significantly lower, according to BofA Securities.

Benzinga

Stodgy Tax Services IPO Looks Like What U.S. Investors Want from China Now

Key Takeaways: Lichen China has filed for an IPO to raise about $25 million, positioning itself as a potential consolidator in China’s vast, but highly fragmented, tax services market Company points out it should be able to avoid many of the recent controversies now dogging U.S.-listed Chinese stocks By Doug…

Benzinga

Why This Analyst Remains Bullish On Upstart Holdings, While Others Cut Their Ratings

Upstart Holdings Inc (NASDAQ: UPST) reported better-than-expected first-quarter results on Monday after the bell. However, shares of the AI consumer lending company tumbled more than 40% as management slashed the 2022 revenue forecast to $1.25 billion.

Benzinga

Vertex Energy Clocks 61% Top-Line Growth In Q1

Vertex Energy Inc (NASDAQ:VTNR) reported first-quarter revenue growth of 60.6% year-over-year to $40.22 million, missing the consensus of $51.69 million. EPS loss was $(0.08) compared to $0.01 a year ago. The gross margin contracted by 466 bps to 3.8%. Vertex's operating loss increased to $(7.27) million from $(0.76) million a year ago.…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Why Vroom Shares Are Racing Higher Today

Vroom Inc (NASDAQ: VRM) shares are trading higher Tuesday after the company announced better-than-expected financial results.

Benzinga

GoodRx Shares Tumble As FY22 Guidance Hit By Grocery Chain Prescription Dispute

GoodRx Holdings Inc (NASDAQ: GDRX) shares fell after it expects FY22 revenue to take a hit due to recent actions by one grocery store chain that represents a sizable chunk of its grocery prescription business.

Benzinga

CEVA Clocks 35% Revenue Growth In Q1 Powered By Dominance In Wireless IP

CEVA, Inc (NASDAQ:CEVA) reported first-quarter FY22 revenue growth of 35% year-on-year to $34.4 million, beating the consensus of $32.9 million. Segments: Licensing, non-recurring engineering (NRE), and related revenue increased 56% Y/Y to $22.4 million. Royalty revenue rose 9% Y/Y to $12 million. The quarter saw 14 license agreements, including 3 with first-time customers. Non-GAAP…

Benzinga

Earnings Outlook For ADMA Biologics

ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that ADMA Biologics will report an earnings per share (EPS) of $-0.08.

Benzinga

Onconova Therapeutics Earnings Preview

Onconova Therapeutics (NASDAQ:ONTX) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that Onconova Therapeutics will report an earnings per share (EPS) of $-0.19.

Benzinga

A Preview Of TRACON Pharmaceuticals's Earnings

TRACON Pharmaceuticals (NASDAQ:TCON) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that TRACON Pharmaceuticals will report an earnings per share (EPS) of $-0.42.

Benzinga

Earnings Preview For BioCardia

BioCardia (NASDAQ:BCDA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that BioCardia will report an earnings per share (EPS) of $-0.24.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Analyst Ratings for Rover Group

Analysts have provided the following ratings for Rover Group (NASDAQ:ROVR) within the last quarter:

Benzinga

Yield10 Bioscience Earnings Preview

Yield10 Bioscience (NASDAQ:YTEN) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that Yield10 Bioscience will report an earnings per share (EPS) of $-0.65.

Benzinga

ACV Auctions's Earnings Outlook

ACV Auctions (NASDAQ:ACVA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that ACV Auctions will report an earnings per share (EPS) of $-0.16.

Benzinga

Analyst Ratings for bluebird bio

Over the past 3 months, 6 analysts have published their opinion on bluebird bio (NASDAQ:BLUE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

A Preview Of icad's Earnings

icad (NASDAQ:ICAD) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that icad will report an earnings per share (EPS) of $-0.12.

Benzinga

Xeris Pharmaceuticals's Earnings Outlook

Xeris Pharmaceuticals (NASDAQ:XERS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that Xeris Pharmaceuticals will report an earnings per share (EPS) of $-0.25.

Benzinga

Why Moderna Shares Are Trading Lower Following Novavax's Earnings Report

Moderna Inc (NASDAQ: MRNA) shares are trading lower by 3.15% at $131.52.

Benzinga

Looking Into Lucid Gr's Recent Short Interest

Lucid Gr's (NASDAQ:LCID) short percent of float has risen 3.74% since its last report. The company recently reported that it has 111.08 million shares sold short, which is 20.8% of all regular shares that are available for trading.

Benzinga

Where Zynga Stands With Analysts

Over the past 3 months, 4 analysts have published their opinion on Zynga (NASDAQ:ZNGA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

So What's Going On With Affirm Shares Today?

Affirm Holdings Inc (NASDAQ: AFRM) shares are trading lower by 16.66% at $17.16.

Benzinga

Exela Shares Plunge Post Q1 Miss

Exela Technologies, Inc (NASDAQ:XELA) reported a preliminary first-quarter FY22 revenue decline of 6.9% year-on-year to $279.4 million, missing the consensus of $284.9 million. Segments: Revenue for the Information and Transaction Processing Solutions segment declined 11.6% Y/Y to $205 million due to the impact from COVID, transition revenue, staffing shortage, and currency changes. Healthcare Solutions'…

1 … 439 440 441 442

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.